Celator Shines At ASCO, Highlights Upside For Jazz
This article was originally published in The Pink Sheet Daily
Executive Summary
With proof of concept for its CombiPlex platform in the form of Phase III results for Vyxeos in acute myeloid leukemia, the $1.5bn purchase price paid by Jazz bought more than a promising late-stage asset.